Abstract
Background:
The American Joint Commission on Cancer (AJCC) identifies five rare variants of prostate adenocarcinoma: mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine including small cell. No prior study has comprehensively detailed incidence and outcomes for all AJCC variants of prostate cancer.
Methods:
We used the Surveillance, Epidemiology and End Results (SEER) program to analyze prostate cancers diagnosed from 1973 to 2008. Cases of mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine carcinoma were identified, along with cases of non-variant adenocarcinoma for comparison. Age-adjusted incidence rates (IRs) and overall survival (OS) were evaluated and stratified by race, age, stage and PSA. All IRs represent the number of cases per million people per year.
Results:
Each variant is rare, with IRs between 0.03 (adenosquamous) and 0.61 (mucinous). There was a significant difference in incidence between Caucasian and African American patients with mucinous adenocarcinoma. Median OS varied ranged from 10.0 months in neuroendocrine carcinoma to 125.0 months in mucinous adenocarcinoma. In all, 5-year OS ranged from 12.6% in neuroendocrine carcinoma to 75.1% in mucinous adenocarcinoma. There was a significant difference in survival between Caucasian and African American patients for mucinous adenocarcinoma (median survival 144.0 vs 99.0 months, P<0.01). African American patients with mucinous adenocarcinoma also presented with more advanced stage disease compared with Caucasian patients. Multivariate analysis demonstrated that African American race was not associated with worse survival when corrected for stage.
Conclusions:
There are differences in IRs and OS among rare variants of prostate cancer. For mucinous adenocarcinoma, there are significant differences in incidence and survival between Caucasian and African American patients. These differences should be considered in clinical decision making for patients with these malignancies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Seigel R, Ward E, Brawley O, Jemal A . Cancer Statistics, 2011. CA Cancer J Clin 2011; 61: 212–236.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). The AJCC Staging Manual, 7th edn. New York, NY, Springer, 2007.
Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Available from: http://seer.cancer.gov/.
ICD-0-3: International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organization, 2000.
Epstein JH, Lieberman PH . Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol 1985; 4: 299–308.
Osunkoya AO, Nielsen ME, Epstein JI . Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol 2008; 3: 468–472.
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15 year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555–565.
Millar EK, Sharma NK, Lessels AM . Ductal (endometrioid) carcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 1996; 29: 11–19.
Hertell JD, Humphrey PA . Ductal adenocarcinoma of the prostate. J Urol 2011; 186: 277–278.
Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A et al. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 2009; 115: 2872–2880.
Warner JN, Nakamura LY, Pacelli A, Humphreys MR, Castle EP . Primary signet ring cell carcinoma of the prostate. Mayo Clin Proc 2010; 85: 1130–1136.
Abbas F, Civantos F, Benedetto P, Soloway MS . Small cell carcinoma of the bladder and prostate. Urology 1995; 46: 617–630.
Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007; 110: 1729–1737.
Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI . Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol 2004; 5: 651–657.
Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R . Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int 2008; 102: 1369–1374.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Marcus, D., Goodman, M., Jani, A. et al. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 15, 283–288 (2012). https://doi.org/10.1038/pcan.2012.4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2012.4
Keywords
This article is cited by
-
PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies
European Radiology (2023)
-
Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases
Diagnostic Pathology (2021)
-
Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report
BMC Medical Genomics (2021)
-
Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients
EJNMMI Research (2020)
-
Mucinous and secondary tumors of the prostate
Modern Pathology (2018)